A predictive model of immune recovery for DTG + 3TC and DTG + RPV used as switching strategies in HIV+ patients

J Antimicrob Chemother. 2022 Nov 28;77(12):3519-3523. doi: 10.1093/jac/dkac354.

Authors

Jesús Troya¹, Roberto Pedrero-Tomé^{2

3}, Carlos Dueñas⁴, Luis Buzón⁵

Affiliations

¹ Department of Internal Medicine, Infanta Leonor University Hospital, Madrid, Spain.
² Infanta Leonor University Hospital Research and Innovation Foundation, Madrid, Spain.
³ EPINUT Research Group, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
⁴ Clínico Universitario Valladolid Hospital, Faculty of Medicine, University of Valladolid, Valladolid, Spain.
⁵ Burgos Hospital, Burgos, Spain.

PMID: 36245072
DOI: 10.1093/jac/dkac354

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents* / therapeutic use
HIV Infections* / drug therapy
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Lamivudine / therapeutic use
Oxazines / therapeutic use
Pyridones / therapeutic use
Rilpivirine / therapeutic use

Substances

Lamivudine
Anti-HIV Agents
Rilpivirine
Heterocyclic Compounds, 3-Ring
Pyridones
Oxazines